Triazine Dione Crystal Forms for Stability and Flowability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertrophic cardiomyopathy (HCM) focus on symptom relief rather than addressing the root cause, and existing triazine dione derivatives lack stable crystal forms with good physicochemical properties, leading to issues like poor stability and agglomeration.
Innovation Solution
Development of specific crystal forms of (S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione with defined X-ray diffraction patterns and preparation methods using various solvents and crystallization techniques to enhance stability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If amorphous drug products are used, then manufacturing is easier, but product stability deteriorates and flowability worsens
Solution Approach 1:
The patent applies phase transition by transforming the amorphous drug substance into different crystal forms (Crystal Form I, Crystal Form II, Crystal Form III) through controlled crystallization processes. This phase transition from amorphous to crystalline state resolves the contradiction by providing stable, filterable crystal structures while maintaining manufacturability through defined crystallization methods
2Ease of manufacture
If amorphous drug products are used, then manufacturing is easier, but flowability worsens due to agglomeration
Solution Approach 1:
The patent transforms amorphous material into well-defined crystal forms through controlled crystallization. The resulting crystals exhibit improved flowability and reduced agglomeration compared to amorphous forms, while the crystallization process itself provides a manufacturable route from the original amorphous material
3Reliability
If multiple crystal forms exist, then stability can be optimized, but manufacturing precision deteriorates due to crystal form changes
Solution Approach 1:
The patent defines specific crystallization parameters (solvent composition, temperature, pH) for each crystal form to enable precise control over crystal form generation. This resolves the contradiction by providing manufacturing conditions that reliably produce the desired crystal form with high purity, preventing unwanted crystal form changes
Solution Approach 2:
The patent uses X-ray diffraction (XRD) patterns as feedback to identify and characterize different crystal forms. This analytical feedback mechanism enables monitoring and control of crystal form purity during manufacturing, ensuring consistent production of the desired crystal form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms provide improved chemical stability and purity, enabling effective inhibition of myosin ATPase and potential therapeutic benefits for HCM and other myosin-related disorders.
Implementation Method 1
the compound has a very good inhibitory effect on myosin ATPase
Implementation Method 2
an X-ray powder diffraction pattern represented by 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks
Data Source
AI summary
The present disclosure relates to crystal forms of a triazine dione derivative and a preparation method therefor. Specifically, the present disclosure relates to different crystal forms of (S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione and a preparation method therefor. The crystal forms of (S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione provided by the present disclosure have good stability and can be better used for clinical treatment.